SCHEDULE: OrbiMed Discloses 7.3% Stake in C4 Therapeutics

OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly filed an amended Schedule 13G, reporting a combined beneficial ownership of 7.3% in C4 Therapeutics, Inc. as of September 30, 2025.

Summary

• OrbiMed Advisors LLC and OrbiMed Capital LLC, both Delaware-organized investment advisers, have filed an Amendment No. 2 to their Schedule 13G for C4 Therapeutics, Inc.
• As of September 30, 2025, OrbiMed Advisors LLC beneficially owns 1,666,800 shares, representing 2.3% of the common stock.
• OrbiMed Capital LLC beneficially owns 3,568,346 shares, representing 5.0% of the common stock.
• The aggregate beneficial ownership by both reporting persons is 5,235,146 shares, totaling 7.3% of the class.
• The shares are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing control of C4 Therapeutics, Inc.
• Carl L. Gordon, a member of the management committee for OrbiMed, disclaims beneficial ownership of the shares reported.

Sentiment

Score: 6

Explanation: The filing indicates a substantial and continued institutional investment by OrbiMed, a reputable healthcare-focused firm, in C4 Therapeutics. While it's a routine ownership disclosure, the size of the stake (7.3% combined) can be interpreted as a vote of confidence in the company's long-term prospects, contributing to a slightly positive sentiment.

Positives

• Significant institutional investment by OrbiMed, a prominent healthcare-focused investment firm, signals confidence in C4 Therapeutics.
• OrbiMed Capital LLC's 5.0% stake indicates a substantial position by a specialized investor.

Negatives

• No specific negative information is disclosed in this beneficial ownership report.

Risks

• No specific risks related to C4 Therapeutics, Inc. are mentioned in this beneficial ownership filing.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding C4 Therapeutics, Inc.'s future outlook.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
• Each of the undersigned agrees to be responsible for the timely filing of this Schedule 13G and for the completeness and accuracy of the information concerning itself contained therein.

Industry Context

The disclosure of a significant stake by OrbiMed, a specialized healthcare investment firm, is common in the biotechnology and pharmaceutical sectors. Such investments often reflect a long-term view on the potential of a company's drug pipeline or technology, aligning with broader industry trends of institutional support for innovative life science companies.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 7.3% stake may instill confidence and potentially influence market perception of the stock.
• Management: Awareness of a large institutional holder may influence strategic decisions, though the filing explicitly states the shares are not held for control purposes.

Next Steps

• No specific future actions or milestones for C4 Therapeutics, Inc. are mentioned in this beneficial ownership filing.

Key Dates

Keywords

C4 Therapeutics, OrbiMed, Schedule 13G, beneficial ownership, institutional investment, biotech, pharmaceutical, healthcare